Search
loncastuximab tesirine-lpyl (Zynlonta)
Indications:
- treatment of diffuse large B-cell lymphoma
Contraindications:
- pregnancy
Dosage:
- 0.15 mg/kg every 3 weeks for 2 cycles
- 0.075 mg/kg every 3 weeks for subsequent cycles
- dexamethasone 4 mg PO or IV BID for 3 days beginning the day before administering Zynlonta
* 10 mg as lyophilized powder for reconstitution & further dilution
* reconstitute in 2.2 mL of Sterile Water for Injection, USP with the stream directed toward the inside wall of the vial to obtain a final concentration of 5 mg/mL
* store reconstituted solution in the vial for up to 4 hours refrigerated or at room temperature; do not freeze
Adverse effects:
- >= 20%
- fatigue, nausea, musculoskeletal pain
- laboratory
- thrombocytopenia, increased serum GGT, neutropenia, anemia, hyperglycemia, serum transaminase elevation, hypoalbuminemia
- effusion & edema
- pleural effusion, pericardial effusion, ascites, peripheral edema
- myelosuppressioon
- infections
- cutaneous reactions: photosensitivity
- fetus, embryo harm
Mechanism of action:
- CD19-directed antibody & alkylating agent conjugate
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
ZYNLONTA (loncastuximab tesirine-lpyl) for injection, for intravenous use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf